Tuhura Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tuhura Biosciences, Inc. (Nasdaq: HURA) on August 18, 2026. The filing reports on the results of the Company's 2026 Annual Meeting of Stockholders held on the same date and the subsequent issuance of unregistered equity securities.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or margin data. However, it references a previously disclosed $50 million revolving credit facility with Parkview Holdings One LLC. The Company is issuing 1,878,287 shares of common stock as a loan fee in connection with this facility.
Material Changes and Corporate Actions
- Equity Issuance: Following stockholder approval, the Company will issue 1,878,287 shares of common stock to Parkview Holdings One LLC as a loan fee. This issuance is exempt from registration under Section 4(a)(2) and Regulation D of the Securities Act.
- Capital Structure: As of the June 26, 2026 record date, 63,682,528 shares of common stock were outstanding. At the meeting, 43,034,024 shares were present in person or by proxy, constituting a quorum.
Stockholder Voting Results and Management Commentary
Stockholders approved all proposals presented at the 2026 Annual Meeting:
- Proposal One (Election of Directors): All six nominees (James Bianco, James Manuso, Alan List, George Ng, Robert E. Hoffman, and Craig Tendler) were elected.
- Proposal Two (Nasdaq Proposal): Approved the issuance of the 1,878,287 Loan Fee Shares to satisfy Nasdaq Listing Rule 5635(d). Votes: 28,128,581 For; 517,896 Against.
- Proposal Three (Executive Compensation): Advisory vote on named executive officer compensation was approved. Votes: 26,125,280 For; 2,484,951 Against.
- Proposal Four (Say-on-Frequency): Stockholders voted to conduct future advisory compensation votes every three years. Votes: 14,472,313 for Three Years; 13,945,985 for One Year.
- Proposal Five (Auditor Ratification): Ratified the appointment of Cherry Bekaert LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes: 42,911,888 For; 39,928 Against.
- Proposal Six (Adjournment): Approved, though no motion to adjourn was made as it was deemed unnecessary.
Investor Verification Checklist
- Verify the final issuance date and settlement of the 1,878,287 Loan Fee Shares to Parkview Holdings One LLC.
- Review the terms of the $50 million revolving credit facility disclosed in the April 22, 2026 Form 8-K to understand interest rates, covenants, and maturity.
- Confirm the updated share count and potential dilution impact following the issuance of the Loan Fee Shares.
- Monitor future filings for the Company's financial performance and liquidity status, as this 8-K contains no operational financial results.